Piramal Pharma

Piramal Pharma

204.35
+2.12
(1.05%)
Market Cap
27,163.19 Cr
EPS
0.69
PE Ratio
301.57
Dividend Yield
0.07 %
Industry
Healthcare
52 Week High
307.90
52 Week Low
164.15
PB Ratio
3.30
Debt to Equity
0.60
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from9 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,702.20
#1 4,08,414.80
35.57
#1 54,729.00
12.06
#1 10,980
-18.99
55.97
6,584.00
1,74,784.51
80.22
9,712.00
0.89
2,191
23.05
40.37
1,572.00
1,26,971.67
22.93
28,409.50
7.12
5,291
9.88
70.77
3,622.90
1,21,969.00
63.65
11,539.40
6.99
1,911
19.91
72.46
1,287.40
1,07,442.68
#1 18.77
33,741.20
16.73
5,725
1.26
54.50
2,541.60
1,04,899.14
61.83
12,744.20
19.57
2,007
-10.91
52.39
980.10
98,620.99
21.15
23,511.00
13.82
4,615
-0.19
54.96
1,960.50
89,535.15
27.44
22,909.50
#1 19.94
3,306
#1 112.49
53.75
32,895.00
69,899.58
50.72
6,684.70
10.80
1,414
27.83
42.22
1,127.00
65,456.34
18.86
31,378.10
17.55
3,366
-0.50
47.15
Forecast
Actual
Growth Rate
Revenue Growth
14.23 %
Net Income Growth
-109.54 %
Cash Flow Change
-11.17 %
ROE
-108.36 %
ROCE
173.33 %
EBITDA Margin (Avg.)
40.67 %

Quarterly Financial Results

Quarterly Financials
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
1,345
1,612
1,709
2,229
1,574
1,777
1,814
2,196
1,802
1,980
2,034
2,591
1,993
2,320
2,233
2,812
Expenses
1,197
1,381
1,314
1,733
1,465
1,554
1,629
1,812
1,617
1,646
1,723
2,053
1,747
1,900
1,867
2,193
EBITDA
148
231
395
495
109
223
185
384
185
334
312
538
246
420
367
619
Operating Profit %
9 %
12 %
15 %
19 %
1 %
10 %
5 %
16 %
8 %
14 %
12 %
20 %
10 %
15 %
15 %
20 %
Depreciation
136
138
147
165
162
166
164
184
174
185
186
196
185
192
197
243
Interest
42
49
50
57
62
83
95
104
119
110
106
114
107
108
103
104
Profit Before Tax
-30
44
198
273
-115
-26
-74
95
-107
40
19
228
-45
120
67
273
Tax
-2
7
35
69
-6
11
17
45
-9
35
9
126
44
98
63
119
Net Profit
-28
37
163
204
-109
-37
-90
50
-99
5
10
101
-89
23
4
154
EPS in ₹
0.00
0.31
1.38
1.72
-0.92
-0.31
-0.76
0.42
-0.83
0.04
0.08
0.77
-0.67
0.17
0.03
1.16

Balance Sheet

Balance Sheet
2021
2022
2023
2024
2025
Total Assets
10,900
12,797
14,523
15,312
15,678
Fixed Assets
6,106
6,879
7,469
7,990
8,133
Current Assets
3,649
4,067
4,836
5,465
5,797
Capital Work in Progress
627
1,172
1,419
1,116
977
Investments
123
267
639
385
291
Other Assets
4,045
4,478
4,996
5,821
6,277
Total Liabilities
10,900
12,797
14,523
15,312
15,678
Current Liabilities
2,490
3,033
3,843
4,369
3,766
Non Current Liabilities
2,805
3,067
3,906
3,031
3,786
Total Equity
5,605
6,697
6,774
7,911
8,126
Reserve & Surplus
4,610
5,511
5,580
6,588
6,801
Share Capital
995
1,186
1,193
1,323
1,324

Cash Flow

Cash Flow
2021
2022
2023
2024
2025
Net Cash Flow
110
-177
-32
166
-37
Investing Activities
-4,464
-1,737
-1,334
-416
-488
Operating Activities
598
766
484
1,005
892
Financing Activities
3,977
794
818
-422
-441

Share Holding

% Holding
Sept 2022
Oct 2022
Dec 2022
Mar 2023
Jun 2023
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
34.79 %
0.00 %
34.79 %
34.79 %
34.79 %
35.02 %
35.02 %
35.02 %
35.02 %
34.95 %
34.95 %
34.95 %
34.95 %
34.86 %
FIIs
20.00 %
0.00 %
20.00 %
20.00 %
20.00 %
18.04 %
32.37 %
32.51 %
30.59 %
31.42 %
31.73 %
31.68 %
31.49 %
30.86 %
DIIs
4.86 %
0.00 %
5.28 %
4.99 %
5.49 %
7.83 %
8.02 %
9.68 %
12.12 %
12.95 %
13.81 %
14.10 %
14.78 %
14.26 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.42 %
0.00 %
11.80 %
13.94 %
16.77 %
16.81 %
16.95 %
15.57 %
15.13 %
13.94 %
13.29 %
13.29 %
13.11 %
14.07 %
Others
32.92 %
100.00 %
28.14 %
26.29 %
22.95 %
22.30 %
7.64 %
7.22 %
7.14 %
6.74 %
6.22 %
5.98 %
5.66 %
5.95 %
No of Share Holders
1,79,957
1,79,948
2,29,960
2,41,359
2,77,270
2,95,773
2,97,225
2,92,312
2,97,996
3,06,398
3,59,751
4,18,442
4,32,843
4,58,430

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.11 0.14
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.84 0.00 0.05 0.07

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Jul 2025 199.95 202.23
28 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jul 2025 216.88 202.23
16 Jul 2025 DIVIDEND Dividend
₹ 0.14 /share
16 Jul 2025 214.90 216.22
14 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 May 2025 214.95 214.90
28 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jan 2025 221.25 224.00
23 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Oct 2024 221.30 215.15
26 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Jul 2024 157.10 166.30
12 Jul 2024 DIVIDEND Dividend
₹ 0.11 /share
12 Jul 2024 148.05 151.60
02 Aug 2023 RIGHTS Rights
5:46
02 Aug 2023 101.95 103.86

Announcements

Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Grant Of Stock Options46 minutes ago
Announcement under Regulation 30 (LODR)-Restructuring6 days ago
Announcement under Regulation 30 (LODR)-Credit Rating7 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
Board Meeting Intimation for Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)10 days ago
Announcement Under Regulation 30 (LODR) - ESG RatingJul 10, 2025
Company Update On LitigationJul 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 02, 2025
Notice Of The 5Th Annual General Meeting (AGM) And Annual Report For The Financial Year 2024-25Jul 02, 2025
Reg. 34 (1) Annual Report.Jul 02, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 26, 2025
Corporate Action-Board to consider DividendJun 13, 2025
Intimation Of Record Date For Payment Of Final DividendJun 13, 2025
Intimation Of 5Th Annual General Meeting To Be Held On Wednesday July 30 2025Jun 13, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations)Jun 13, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sJun 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 02, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 26, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 14, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 14, 2025
Audited Financial Results (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St March 2025May 14, 2025
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited (Company) Held On 14Th May 2025May 14, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) - Capacity Expansion Of Lexington And Riverview SitesMay 12, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) -Successful Closure Of US FDA Inspection At Piramal PharmaS Manufacturing Facility Located At TurbheMay 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 29, 2025
Board Meeting Intimation for Board Meeting Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Apr 29, 2025
Announcement under Regulation 30 (LODR)-AcquisitionApr 23, 2025
Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Apr 01, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 20, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 19, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) -US FDA Inspection At Piramal PharmaS Facility Located At TurbhFeb 18, 2025
Intimation For Change In Domain Name And Generic E-Mail ID Of The Registrar And Share Transfer Agent (RTA) Of CompanyFeb 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 17, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Extension Of Timeline Communicated For Sale Of CompanyS Unit Situated At ThaneJan 31, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 29, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) - Issuance Of CorpJan 29, 2025

Technical Indicators

RSI(14)
Neutral
45.32
ATR(14)
Less Volatile
5.42
STOCH(9,6)
Neutral
27.33
STOCH RSI(14)
Oversold
0.85
MACD(12,26)
Bearish
-0.56
ADX(14)
Weak Trend
14.68
UO(9)
Bearish
34.97
ROC(12)
Uptrend But Slowing Down
0.39
WillR(14)
Oversold
-81.88

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HSBC Midcap Fund Direct-Growth
0.17%
-5478400
-1.00%
-1.11%
HDFC Flexi Cap Direct Plan-Growth
2.24%
3152865
-0.06%
-0.08%
Kotak Arbitrage Fund Direct-Growth
0.07%
2285000
0.07%
0.07%
Bandhan Small Cap Fund Direct-Growth
0.82%
1767154
0.21%
0.23%
HDFC Focused Fund Direct-Growth
2.44%
1000000
-0.09%
-0.29%
Franklin India Opportunities Direct Fund-Growth
0.72%
-851652
-0.30%
-0.39%
Edelweiss Business Cycle Fund Direct-Growth
0.00%
-693058
-0.78%
-0.83%
Mahindra Manulife Mid Cap Fund Direct - Growth
0.00%
-600000
-0.33%
-0.36%
HDFC Business Cycle Fund Direct - Growth
1.32%
570000
0.34%
0.66%
Mahindra Manulife Business Cycle Fund Direct - Growth
0.00%
-500500
-0.85%
-0.90%
Mahindra Manulife Small Cap Fund Direct - Growth
0.00%
-500000
-0.27%
-2.16%
Nippon India Nifty 500 Momentum 50 Index Fund Direct-Growth
0.00%
-420599
-1.00%
-1.08%
Franklin India Multi Cap Fund Direct-Growth
0.39%
-345415
-0.17%
-0.21%
Motilal Oswal Nifty 500 Momentum 50 Index Fund Direct-Growth
0.00%
-317976
-1.00%
-1.08%
Canara Robeco Multi Cap Fund Direct - Growth
0.51%
-272431
-0.17%
-0.42%
Invesco India Arbitrage Fund Direct-Growth
0.02%
237500
0.02%
0.02%
LIC MF Flexi Cap Fund Direct-Growth
1.42%
-212337
-0.53%
-2.01%
Canara Robeco Flexi Cap Fund Direct-Growth
0.10%
-172431
-0.03%
-0.10%
HDFC MNC Fund Direct - Growth
2.25%
160000
0.48%
1.32%
LIC MF Manufacturing Fund Direct-Growth
0.97%
84202
0.17%
0.06%
Edelweiss Arbitrage Fund Direct-Growth
0.01%
77500
0.01%
0.01%
Aditya Birla Sun Life Arbitrage Fund Direct-Growth
0.01%
70000
0.01%
0.01%
Kotak Quant Fund Direct - Growth
0.88%
-40387
-0.16%
-0.25%
LIC MF Value Fund Direct - Growth
0.57%
-37210
-0.49%
-1.51%
Axis Nifty500 Momentum 50 Index Fund Direct-Growth
0.00%
-32578
-0.99%
-1.08%

About Piramal Pharma

Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics (CHG) business, and an India Consumer Healthcare (ICH) business. Piramal Pharma Solutions provides integrated drug discovery, development, and manufacturing services. The company has a joint venture with Allergan in ophthalmology and a minority investment in Yapan Bio for biologics and vaccines. It is a leading player in India's self-care space with established brands. The company specializes in niche areas such as highly potent APIs, antibody drug conjugates, and biologics. In 2022, Piramal Pharma Limited was listed on the BSE and NSE following a demerger from Piramal Enterprises Limited.
Chairperson NameNandini Piramal